These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22926630)

  • 1. Advanced hybrid stress testing: a potential new paradigm combining exercise and pharmacologic stress.
    Thomas GS; Hundal HS; Ellestad MH
    J Nucl Cardiol; 2012 Oct; 19(5):887-90. PubMed ID: 22926630
    [No Abstract]   [Full Text] [Related]  

  • 2. Indirect evidence of sympathetic stimulation by regadenoson.
    Farris GR; Hage FG; Kumar V; Iskandrian AE
    J Nucl Cardiol; 2019 Apr; 26(2):684-687. PubMed ID: 29948894
    [No Abstract]   [Full Text] [Related]  

  • 3. The heart rate response to regadenoson in patients with atrial fibrillation.
    Uzendu AI; Iskandrian A; Hage FG
    J Nucl Cardiol; 2018 Jun; 25(3):1012-1016. PubMed ID: 28856613
    [No Abstract]   [Full Text] [Related]  

  • 4. Daily Caffeine Consumption Is Associated with Decreased Incidence of Symptoms and Hemodynamic Changes During Pharmacologic Stress with Regadenoson.
    Posch MI; Kay MD; Harhash AA; Huang JJ; Krupinski EA; Abidov A; McMillan NA; Kuo PH
    J Nucl Med Technol; 2020 Mar; 48(1):73-76. PubMed ID: 31604901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test.
    Partington SL; Lanka V; Hainer J; Blankstein R; Skali H; Forman DE; Di Carli MF; Dorbala S
    J Nucl Cardiol; 2012 Oct; 19(5):970-8. PubMed ID: 22565239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMPD1 polymorphism and response to regadenoson.
    Saab R; Zouk AN; Mastouri R; Skaar TC; Philips S; Kreutz RP
    Pharmacogenomics; 2015 Nov; 16(16):1807-15. PubMed ID: 26554440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An example of the clinical selectivity of regadenoson for the A2a adenosine receptor.
    Miyamoto MI; Clarke KA; Thomas GS; Belardinelli L
    Am Heart Hosp J; 2009; 7(2):E118-21. PubMed ID: 20354957
    [No Abstract]   [Full Text] [Related]  

  • 8. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands].
    Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regadenoson myocardial perfusion imaging predicts prognosis in patients with either left bundle branch block or a ventricular paced rhythm.
    Thomas GS; Taghavi A
    J Nucl Cardiol; 2021 Jun; 28(3):978-980. PubMed ID: 31385224
    [No Abstract]   [Full Text] [Related]  

  • 10. Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications.
    Palani G; Ananthasubramaniam K
    Cardiol Rev; 2013; 21(1):42-8. PubMed ID: 22643345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New stress test agents reduce adverse effects.
    Mitka M
    JAMA; 2008 May; 299(18):2140. PubMed ID: 18477777
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances in pharmacologic stress agents: focus on regadenoson.
    Johnson SG; Peters S
    J Nucl Med Technol; 2010 Sep; 38(3):163-71. PubMed ID: 20724531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regadenoson and exercise myocardial perfusion imaging: the courtship continues.
    Hundal HS; Thomas GS
    J Nucl Cardiol; 2013 Jun; 20(3):324-8. PubMed ID: 23456829
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of intravenous adenosine and intravenous regadenoson for the measurement of pressure-derived coronary fractional flow reserve.
    Arumugham P; Figueredo VM; Patel PB; Morris DL
    EuroIntervention; 2013 Feb; 8(10):1166-71. PubMed ID: 23164748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regadenoson, a novel pharmacologic stress agent for use in myocardial perfusion imaging, does not have a direct effect on the QT interval in conscious dogs.
    Zhao G; Serpllion S; Shryock J; Messina E; Xu X; Ochoa M; Belardinelli L; Hintze TH
    J Cardiovasc Pharmacol; 2008 Nov; 52(5):467-73. PubMed ID: 19033827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of hemodynamic and stress testing variables in patients undergoing regadenoson stress myocardial perfusion imaging to regadenoson with adjunctive low-level exercise myocardial perfusion imaging.
    Cabrera R; Husain Z; Palani G; Karthikeyan AS; Choudhry Z; Dhanalakota S; Peterson E; Ananthasubramaniam K
    J Nucl Cardiol; 2013 Jun; 20(3):336-43; quiz 344-5. PubMed ID: 23430361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Safety of Adenosine and Regadenoson in Patients Undergoing Outpatient Cardiac Stress Testing.
    Brink HL; Dickerson JA; Stephens JA; Pickworth KK
    Pharmacotherapy; 2015 Dec; 35(12):1117-23. PubMed ID: 26684552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common genetic polymorphisms of adenosine A2A receptor do not influence response to regadenoson.
    Berlacher M; Mastouri R; Philips S; Skaar TC; Kreutz RP
    Pharmacogenomics; 2017 Apr; 18(6):523-529. PubMed ID: 28358597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regadenoson stress for myocardial perfusion imaging.
    Reyes E
    Future Cardiol; 2016 Jan; 12(1):59-67. PubMed ID: 26639775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capturing maximal coronary vasodilation for myocardial perfusion imaging: is timing everything?
    Dilsizian V; Narula J
    JACC Cardiovasc Imaging; 2015 Apr; 8(4):499-500. PubMed ID: 25882579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.